I have obtained my PH D in Chiba University, Japan and I moved to UAMS from the NIH where I was a postdoctoral fellow at in the laboratory of Dr. Stuart Rudikoff receiving training in Cellular and Molecular Biology training. I characterized the role of the IGF-1 signaling pathway in growth and migration in myeloma cells. This work identified downstream cascades of RAF-MEK-ERK and PI-3K/AKT pathways. I also identified role of Wnt signaling in myeloma cells and mesenchymal stem cells (MSCs) and discovered that interruption of this pathway by Dkk1 leads to suppression of MSC differentiation into osteoblasts (OBs) and to activation of osteoclasts by promoting OB transcription of OPG, which is an important mechanism underlying myeloma bone disease. At Myeloma center of UAMS, my identified a critical role of t(14/18)/C-MAF conferring resistance to proteasome inhibition therapy. My second project focuses on identify molecular mechanism of RAS/RAF in MEK inhibition treatment and found that K-RAS mutant upregulated stress-granule formation mediated proteosome resistance in myeloma.